Solís-Ruiz, J. A., Barthe, A., Riegel, G., Saavedra-Díaz, R. O., Gaiddon, C., & Le Lagadec, R. (2020). Light activation of cyclometalated ruthenium complexes drives towards caspase 3 dependent apoptosis in gastric cancer cells. Journal of Inorganic Biochemistry, 208, 111080.
Licona, C., Delhorme, J.-B., Riegel, G., Vidimar, V., Cerón-Camacho, R., Boff, B., Venkatasamy, A., Tomasetto, C., da Silva Figueiredo Celestino Gomes, P., Rognan, D., Freund, J.-N., Le Lagadec, R., Pfeffer, M., Gross, I., Mellitzer, G., & Gaiddon, C. (2020). Anticancer activity of ruthenium and osmium cyclometalated compounds: identification of ABCB1 and EGFR as resistance mechanisms. Inorganic Chemistry Frontiers, 7(3), 678–688.
Miller, J. J., Blanchet, A., Orvain, C., Nouchikian, L., Reviriot, Y., Clarke, R. M., Martelino, D., Wilson, D., Gaiddon, C., & Storr, T. (2019). Bifunctional ligand design for modulating mutant p53 aggregation in cancer. Chemical Science, 10(46), 10802–10814.
Spaety, M.-E., Gries, A., Badie, A., Venkatasamy, A., Romain, B., Orvain, C., Yanagihara, K., Okamoto, K., Jung, A. C., Mellitzer, G., Pfeffer, S., & Gaiddon, C. (2019). HDAC4 Levels Control Sensibility toward Cisplatin in Gastric Cancer via the p53-p73/BIK Pathway. Cancers, 11(11), 1747.
Coliat, P., Ramolu, L., Jégu, J., Gaiddon, C., Jung, A. C., & Pencreach, E. (2019). Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC. Cancers, 11(10).
Liang, Y., Hou, L., Li, L., Li, L., Zhu, L., Wang, Y., Huang, X., Hou, Y., Zhu, D., Zou, H., Gu, Y., Weng, X., Wang, Y., Li, Y., Wu, T., Yao, M., Gross, I., Gaiddon, C., Luo, M., … Meng, X. (2019). Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway. Oncogene.
Job, S., Reyniès, A. de, Heller, B., Weiss, A., Guérin, E., Macabre, C., Ledrappier, S., Bour, C., Wasylyk, C., Etienne-Selloum, N., Brino, L., Gaiddon, C., Wasylyk, B., & Jung, A. C. (2019). Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction. Cancers, 11(6).
Santoro, A., Vileno, B., Palacios, Ò., Peris-Díaz, M. D., Riegel, G., Gaiddon, C., Krężel, A., & Faller, P. (2019). Reactivity of Cu(ii)-, Zn(ii)- and Fe(ii)-thiosemicarbazone complexes with glutathione and metallothionein: from stability to dissociation to transmetallation. Metallomics: Integrated Biometal Science, 11(5), 994–1004.
Vidimar, V., Licona, C., Cerón-Camacho, R., Guerin, E., Coliat, P., Venkatasamy, A., Ali, M., Guenot, D., Le Lagadec, R., Jung, A. C., Freund, J.-N., Pfeffer, M., Mellitzer, G., Sava, G., & Gaiddon, C. (2019). A redox ruthenium compound directly targets PHD2 and inhibits the HIF1 pathway to reduce tumor angiogenesis independently of p53. Cancer Letters, 440–441, 145–155.
Borel, C., Regnier-Gavier, O., Carinato, H., Guihard, S., Antoni, D., Demarchi, M., Sirlin, F., Exinger, D., Petit-Jean, E., Thiery, A., Bronner, G., Schultz, P., Flesch, H., Frasie, V., Prébay, D., Petit, T., Jung, A. C., Burgy, M., & Coliat, P. (2018). Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer. Oncotarget, 9(101), 37581–37588.
Miller, J. J., Orvain, C., Jozi, S., Clarke, R. M., Smith, J. R., Blanchet, A., Gaiddon, C., Warren, J. J., & Storr, T. (2018). Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer. Chemistry (Weinheim an Der Bergstrasse, Germany), 24(67), 17734–17742.
Lam, N. Y. S., Truong, D., Burmeister, H., Babak, M. V., Holtkamp, H. U., Movassaghi, S., Ayine-Tora, D. M., Zafar, A., Kubanik, M., Oehninger, L., Söhnel, T., Reynisson, J., Jamieson, S. M. F., Gaiddon, C., Ott, I., & Hartinger, C. G. (2018). From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents. Inorganic Chemistry, 57(22), 14427–14434.
Minault, Q., Gaiddon, C., Veillon, F., & Venkatasamy, A. (2018). The Champagne sign. Abdominal Radiology (New York), 43(10), 2888–2889.
Chow, M. J., Babak, M. V., Tan, K. W., Cheong, M. C., Pastorin, G., Gaiddon, C., & Ang, W. H. (2018). Induction of the Endoplasmic Reticulum Stress Pathway by Highly Cytotoxic Organoruthenium Schiff-Base Complexes. Molecular Pharmaceutics, 15(8), 3020–3031.
Gass, B., Marrer, E., Bara, S., Ligier, K., Molinié, F., Colonna, M., Daubisse-Marliac, L., Trétarre, B., Lapôtre-Ledoux, B., Woronoff, A.-S., Guizard, A.-V., Bouvier, V., Troussard, X., Gaiddon, C., Klein, D., Velten, M., & Jégu, J. (2018). Use of a case-mix approach to study the trends in the incidence of second primary cancers. Annals of Epidemiology, 28(5), 322–327.
Babak, M. V., Pfaffeneder-Kmen, M., Meier-Menches, S. M., Legina, M. S., Theiner, S., Licona, C., Orvain, C., Hejl, M., Hanif, M., Jakupec, M. A., Keppler, B. K., Gaiddon, C., & Hartinger, C. G. (2018). Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action. Inorganic Chemistry, 57(5), 2851–2864.
Makarchuk, S., Beyer, N., Gaiddon, C., Grange, W., & Hébraud, P. (2018). Holographic Traction Force Microscopy. Scientific Reports, 8(1), 3038.
Manfredelli, S., Delhorme, J.-B., Venkatasamy, A., Gaiddon, C., Brigand, C., Rohr, S., & Romain, B. (2017). Could a Feeding Jejunostomy be Integrated into a Standardized Preoperative Management of Oeso-gastric Junction Adenocarcinoma? Annals of Surgical Oncology, 24(11), 3324–3330.
Chow, M. J., Alfiean, M., Pastorin, G., Gaiddon, C., & Ang, W. H. (2017). Apoptosis-independent organoruthenium anticancer complexes that overcome multidrug resistance: self-assembly and phenotypic screening strategies. Chemical Science, 8(5), 3641–3649.
Estrada‐Montaño, A. S., Ryabov, A. D., Gries, A., Gaiddon, C., & Lagadec, R. L. (2017). Iron(III) Pincer Complexes as a Strategy for Anticancer Studies. European Journal of Inorganic Chemistry, 2017(12), 1673–1678.
Licona, C., Spaety, M.-E., Capuozzo, A., Ali, M., Santamaria, R., Armant, O., Delalande, F., Van Dorsselaer, A., Cianferani, S., Spencer, J., Pfeffer, M., Mellitzer, G., & Gaiddon, C. (2017). A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin. Oncotarget, 8(2), 2568–2584.
Mirghani, H., Jung, A. C., & Fakhry, C. (2017). Primary, secondary and tertiary prevention of human papillomavirus-driven head and neck cancers. European Journal of Cancer (Oxford, England: 1990), 78, 105–115.
Platet, N., Hinkel, I., Richert, L., Murdamoothoo, D., Moufok-Sadoun, A., Vanier, M., Lavalle, P., Gaiddon, C., Vautier, D., Freund, J.-N., & Gross, I. (2017). The tumor suppressor CDX2 opposes pro-metastatic biomechanical modifications of colon cancer cells through organization of the actin cytoskeleton. Cancer Letters, 386, 57–64.
Khalil, G., Orvain, C., Fang, L., Barloy, L., Chaumont, A., Gaiddon, C., Henry, M., Kyritsakas, N., & Mobian, P. (2016). Monomeric Ti(iv)-based complexes incorporating luminescent nitrogen ligands: synthesis, structural characterization, emission spectroscopy and cytotoxic activities. Dalton Transactions (Cambridge, England: 2003), 45(47), 19072–19085.
Bonnin, N., Armandy, E., Carras, J., Ferrandon, S., Battiston-Montagne, P., Aubry, M., Guihard, S., Meyronet, D., Foy, J.-P., Saintigny, P., Ledrappier, S., Jung, A. C., Rimokh, R., Rodriguez-Lafrasse, C., & Poncet, D. (2016). MiR-422a promotes loco-regional recurrence by targeting NT5E/CD73 in head and neck squamous cell carcinoma. Oncotarget, 7(28), 44023–44038.
Chow, M. J., Babak, M. V., Wong, D. Y. Q., Pastorin, G., Gaiddon, C., & Ang, W. H. (2016). Structural Determinants of p53-Independence in Anticancer Ruthenium-Arene Schiff-Base Complexes. Molecular Pharmaceutics, 13(7), 2543–2554.
Chow, M. J., Licona, C., Pastorin, G., Mellitzer, G., Ang, W. H., & Gaiddon, C. (2016). Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance. Chemical Science, 7(7), 4117–4124.
von Grabowiecki, Y., Abreu, P., Blanchard, O., Palamiuc, L., Benosman, S., Mériaux, S., Devignot, V., Gross, I., Mellitzer, G., Gonzalez de Aguilar, J. L., & Gaiddon, C. (2016). Transcriptional activator TAp63 is upregulated in muscular atrophy during ALS and induces the pro-atrophic ubiquitin ligase Trim63. ELife, 5, e10528.
Rico Bautista, H., Saavedra Díaz, R. O., Shen, L. Q., Orvain, C., Gaiddon, C., Le Lagadec, R., & Ryabov, A. D. (2016). Impact of cyclometalated ruthenium(II) complexes on lactate dehydrogenase activity and cytotoxicity in gastric and colon cancer cells. Journal of Inorganic Biochemistry, 163, 28–38.
Jung, A. C., Ray, A.-M., Ramolu, L., Macabre, C., Simon, F., Noulet, F., Blandin, A.-F., Renner, G., Lehmann, M., Choulier, L., Kessler, H., Abecassis, J., Dontenwill, M., & Martin, S. (2015). Caveolin-1-negative head and neck squamous cell carcinoma primary tumors display increased epithelial to mesenchymal transition and prometastatic properties. Oncotarget, 6(39), 41884–41901.
Hanns, E., Job, S., Coliat, P., Wasylyk, C., Ramolu, L., Pencreach, E., Suarez-Carmona, M., Herfs, M., Ledrappier, S., Macabre, C., Abecassis, J., Wasylyk, B., & Jung, A. C. (2015). Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature. Oral Oncology, 51(9), 848–856.
Chamard-Jovenin, C., Jung, A. C., Chesnel, A., Abecassis, J., Flament, S., Ledrappier, S., Macabre, C., Boukhobza, T., & Dumond, H. (2015). From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression. BMC Systems Biology, 9, 28.
Tasan, S., Licona, C., Doulain, P.-E., Michelin, C., Gros, C. P., Le Gendre, P., Harvey, P. D., Paul, C., Gaiddon, C., & Bodio, E. (2015). Gold-phosphine-porphyrin as potential metal-based theranostics. Journal of Biological Inorganic Chemistry: JBIC: A Publication of the Society of Biological Inorganic Chemistry, 20(1), 143–154.
von Grabowiecki, Y., Licona, C., Palamiuc, L., Abreu, P., Vidimar, V., Coowar, D., Mellitzer, G., & Gaiddon, C. (2015). Regulation of a Notch3-Hes1 pathway and protective effect by a tocopherol-omega alkanol chain derivative in muscle atrophy. The Journal of Pharmacology and Experimental Therapeutics, 352(1), 23–32.
Chow, M. J., Licona, C., Yuan Qiang Wong, D., Pastorin, G., Gaiddon, C., & Ang, W. H. (2014). Discovery and investigation of anticancer ruthenium-arene Schiff-base complexes via water-promoted combinatorial three-component assembly. Journal of Medicinal Chemistry, 57(14), 6043–6059.
Klajner, M., Licona, C., Fetzer, L., Hebraud, P., Mellitzer, G., Pfeffer, M., Harlepp, S., & Gaiddon, C. (2014). Subcellular localization and transport kinetics of ruthenium organometallic anticancer compounds in living cells: a dose-dependent role for amino acid and iron transporters. Inorganic Chemistry, 53(10), 5150–5158.
Robertson, E. D., Wasylyk, C., Ye, T., Jung, A. C., & Wasylyk, B. (2014). The oncogenic MicroRNA Hsa-miR-155-5p targets the transcription factor ELK3 and links it to the hypoxia response. PloS One, 9(11), e113050.
Wasylyk, B., Abecassis, J., & Jung, A. C. (2013). Identification of clinically relevant HPV-related HNSCC: in p16 should we trust? Oral Oncology, 49(10), e33-37.
Anthwal, N., Pelling, M., Claxton, S., Mellitzer, G., Collin, C., Kessaris, N., Richardson, W. D., Gradwohl, G., & Ang, S.-L. (2013). Conditional deletion of neurogenin-3 using Nkx2.1iCre results in a mouse model for the central control of feeding, activity and obesity. Disease Models & Mechanisms, 6(5), 1133–1145.
Ennen, M., Klotz, R., Touche, N., Pinel, S., Barbieux, C., Besancenot, V., Brunner, E., Thiebaut, D., Jung, A. C., Ledrappier, S., Domenjoud, L., Abecassis, J., Plénat, F., Grandemange, S., & Becuwe, P. (2013). DDB2: a novel regulator of NF-κB and breast tumor invasion. Cancer Research, 73(16), 5040–5052.
Jung, A. C., Job, S., Ledrappier, S., Macabre, C., Abecassis, J., de Reyniès, A., & Wasylyk, B. (2013). A poor prognosis subtype of HNSCC is consistently observed across methylome, transcriptome, and miRNome analysis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 19(15), 4174–4184.
Jung, A. C. (2013). Can liberating p53 from E6 free patients from HPV-related head and neck tumors? Cell Cycle (Georgetown, Tex.), 12(6), 868.
Boff, B., Gaiddon, C., & Pfeffer, M. (2013). Cancer cell cytotoxicity of cyclometalated compounds obtained with osmium(II) complexes. Inorganic Chemistry, 52(5), 2705–2715.
Jung, A. C., Guihard, S., Krugell, S., Ledrappier, S., Brochot, A., Dalstein, V., Job, S., de Reynies, A., Noël, G., Wasylyk, B., Clavel, C., & Abecassis, J. (2013). CD8-alpha T-cell infiltration in human papillomavirus-related oropharyngeal carcinoma correlates with improved patient prognosis. International Journal of Cancer, 132(2), E26-36.
Vidimar, V., Meng, X., Klajner, M., Licona, C., Fetzer, L., Harlepp, S., Hébraud, P., Sidhoum, M., Sirlin, C., Loeffler, J.-P., Mellitzer, G., Sava, G., Pfeffer, M., & Gaiddon, C. (2012). Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity. Biochemical Pharmacology, 84(11), 1428–1436.
Ribeiro, N., Thuaud, F., Bernard, Y., Gaiddon, C., Cresteil, T., Hild, A., Hirsch, E. C., Michel, P. P., Nebigil, C. G., & Désaubry, L. (2012). Flavaglines as potent anticancer and cytoprotective agents. Journal of Medicinal Chemistry, 55(22), 10064–10073.
Guihard, S., Ramolu, L., Macabre, C., Wasylyk, B., Noël, G., Abecassis, J., & Jung, A. C. (2012). The NEDD8 conjugation pathway regulates p53 transcriptional activity and head and neck cancer cell sensitivity to ionizing radiation. International Journal of Oncology, 41(4), 1531–1540.
Guihard, S., Jung, A. C., & Noël, G. (2012). [High-risk human papilloma virus associated oropharynx squamous cell carcinomas: clinical, biological implications and therapeutical perspectives]. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 16(1), 34–43.
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2012). Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. Journal of Inorganic Biochemistry, 106(1), 90–99.
Benosman, S., Meng, X., Von Grabowiecki, Y., Palamiuc, L., Hritcu, L., Gross, I., Mellitzer, G., Taya, Y., Loeffler, J.-P., & Gaiddon, C. (2011). Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons. The Journal of Biological Chemistry, 286(50), 43013–43025.
Scroll to top